Showing results (921-930 of 4,514) with videos related to

Sort By:
Pageof 452
Future Oncology (London, England)|November 28, 2025
Long-term safety and effectiveness of ruxolitinib in Japanese patients with polycythemia vera: a post-marketing studyTomoko Hayashi, Wataru Hongo, Weizhe Lu
Future Oncology (London, England)|November 11, 2025
Oncologists' preferences for first-line treatment of ALK-positive metastatic NSCLC in the United States: a discrete choice experimentKathryn F Mileham, Laura Panattoni, Grace Gahlon, et al.
Future Oncology (London, England)|November 10, 2025
Comparison of growth pattern in lung adenocarcinoma with L858R and 19DEL EGFR mutationHaiquan Liu, Fang Lu, Ernuo Wang
Future Oncology (London, England)|November 11, 2025
Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP)Alicia K Morgans, Alex Chehrazi-Raffle, Tamim Niazi, et al.
Future Oncology (London, England)|November 21, 2025
Study design and rationale for the NeoTRACE trial: a multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacituzumab govitecan in patients with resectable non-small cell lung cancerFriederike C Althoff, Fabian Acker, Sebastian Koschade, et al.
Future Oncology (London, England)|January 23, 2026
Avelumab real-world use in advanced Merkel cell carcinoma: a systematic review and non-comparative meta-analysisAndreas Freitag, Zhiyi Lan, Hoora Moradian, et al.
Future Oncology (London, England)|December 29, 2025
OPERA-01: a phase III study of palazestrant for ER+, HER2- advanced breast cancer after CDK4/6 inhibitor therapyBarbara Pistilli, Meritxell Bellet Ezquerra, Lucia Del Mastro, et al.
Future Oncology (London, England)|January 12, 2026
Matching-adjusted indirect treatment comparison of A+AVD vs PET-guided ABVD in newly diagnosed advanced Hodgkin lymphomaFjoralba Kristo, Alexa Molinari, Zhiyi Lan, et al.
Future Oncology (London, England)|January 19, 2026
Impact of antiemetic prophylaxis on reducing trastuzumab deruxtecan dose modifications in HER2+/HER2-low breast cancerJunghoon Shin, Ji-Yeon Kim, Hee Kyung Ahn, et al.
Future Oncology (London, England)|August 22, 2025
EGFR Exon 20 insertions in NSCLC: from biology to amivantamab, optimal treatment strategy and emerging therapeuticsNaoki Furuya
Pageof 452